Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.26 USD | -2.27% | +10.38% | -14.18% |
25/06 | Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study | MT |
25/06 | Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.18% | 333.73Cr | |
+16.49% | 12TCr | |
+21.73% | 12TCr | |
+22.18% | 2.7TCr | |
-21.81% | 2.04TCr | |
-16.89% | 1.64TCr | |
-18.81% | 1.59TCr | |
-44.74% | 1.56TCr | |
+62.72% | 1.49TCr | |
+3.09% | 1.36TCr |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Insider Sell: Arrowhead Pharmaceuticals